BIOMERICA INC BMRA
Nasdaq · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1980-03-17
BIOMERICA INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% | 26.6% | 24.8% | 31.5% | 34.9% | 29.7% |
| Operating margin | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% | -35.9% | -46.4% | -26.6% | -16.5% | -16.1% |
| Net margin | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -34.9% | -46.0% | -26.3% | -15.7% | -29.2% |
| FCF margin | — | -99.9% | -103.7% | -2.8% | -74.8% | -64.7% | -45.1% | -23.4% | -14.1% | -5.8% |
| Return on assets | -83.7% | -64.6% | -49.4% | -39.8% | -63.0% | -13.6% | -45.6% | -28.1% | -18.1% | -26.2% |
| Return on equity | -121.1% | -90.7% | -60.9% | -54.4% | -80.7% | -16.5% | -60.1% | -33.9% | -20.2% | -28.7% |
| Current ratio | 2.80 | 3.51 | 6.58 | 4.69 | 7.10 | 10.00 | 3.56 | 5.00 | 7.96 | 9.55 |
Computed from company filings · US · as of 2025-05-31. Facts plus Stocktoria's own computed scores — not investment advice.